

## Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2

Yanqing Huo<sup>1</sup>, Qingbo Li<sup>1</sup>, Xiqian Wang<sup>1</sup>, Xiejia Jiao<sup>1</sup>, Jiachun Zheng<sup>1</sup>, Zhiqiang Li<sup>1</sup> and Xiaohan Pan<sup>2</sup>

<sup>1</sup>Department of Orthopedics, The Second Hospital of Shandong University, Jinan, 250133, Shandong Province, China

<sup>2</sup>Department of Health Management, The Second Hospital of Shandong University, Jinan, 250133, Shandong Province, China

**Published:** June 17, 2026

**Copyright:** © 2026 Huo et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been retracted:** Oncotarget has concluded its investigation of this paper, and the following issues were discovered:

- Figure 4D: The E-cadherin western blot is a duplicate of Figure 4B from a previously submitted article [1]. While the articles share no authors, they originated from the same institution. Additionally, the  $\beta$ -actin blot is a duplicate of the  $\beta$ -actin blot in Figure 4E of an unrelated paper [2].
- Figure 4C: The invasion assay image for MG-63/si-NC overlaps with the Figure 7D invasion image for MG-63/pMALAT1 + si-EZH2.
- Figure 7D: The invasion image for SAOS-2/pMALAT1 was found in a later publication [3] as the HT29/Control in Figure 1D.

The authors did not respond to requests for comment or provide the original data. Consequently, the editorial decision has been made to retract this paper. Oncotarget has reached out to all authors to notify them of this retraction but has received no response.

Original article: Oncotarget. 2017; 8:46993–47006. <https://doi.org/10.18632/oncotarget.16551>

### REFERENCES

1. Li P, Zhang X, Wang H, Wang L, Liu T, Du L, Yang Y, Wang C. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. *Mol Cancer Ther*. 2017; 16:739–51. <https://doi.org/10.1158/1535-7163.MCT-16-0591>. [PubMed] Erratum in: *Mol Cancer Ther*. 2021; 20:451. <https://doi.org/10.1158/1535-7163.MCT-20-1028>. [PubMed]
2. Liu T, Zhang J, Chai Z, Wang G, Cui N, Zhou B. Ginkgo biloba extract EGb 761-induced upregulation of LincRNA-p21 inhibits colorectal cancer metastasis by associating with EZH2. *Oncotarget*. 2017; 8:91614–27. <https://doi.org/10.18632/oncotarget.21345>. [PubMed]. Retraction in: *Oncotarget*. 2025; 16:310. <https://doi.org/10.18632/oncotarget.28525>. [PubMed]
3. Dai W, Mu L, Cui Y, Li Y, Chen P, Xie H, Wang X. Long non-coding RNA CASC2 enhances berberine-induced cytotoxicity in colorectal cancer cells by silencing BCL2. *Mol Med Rep*. 2019; 20:995–1006. <https://doi.org/10.3892/mmr.2019.10326>. [PubMed]